Cargando…

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction

AIMS: Little information is available on sex differences in coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF). We investigated sex‐specific proteomic profiles associated with CMD in patients with HFpEF. METHODS AND RESULTS: Using the prospective multi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandramouli, Chanchal, Ting, Tay W., Tromp, Jasper, Agarwal, Anubha, Svedlund, Sara, Saraste, Antti, Hage, Camilla, Tan, Ru‐San, Beussink‐Nelson, Lauren, Lagerström Fermer, Maria, Gan, Li‐Ming, Lund, Lars, Shah, Sanjiv J., Lam, Carolyn S.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	HFpEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303712/ https://www.ncbi.nlm.nih.gov/pubmed/35060248 http://dx.doi.org/10.1002/ejhf.2435

Ejemplares similares

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
por: Oduah, Mary-Tiffany, et al.
Publicado: (2023)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
por: Patel, Ravi B., et al.
Publicado: (2021)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
por: Vijay, Aishwarya, et al.
Publicado: (2023)

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
por: Prescott, Eva, et al.
Publicado: (2020)

Heart Failure and Multimorbidity in Asia
por: Ang, Nathalie, et al.
Publicado: (2023)

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction
por: Yap, Jonathan, et al.
Publicado: (2019)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
por: Hage, Camilla, et al.
Publicado: (2020)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
por: Sharma, Abhinav, et al.
Publicado: (2022)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure: Insights From ASIAN-HF
por: Aung, Than, et al.
Publicado: (2021)

Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia
por: Lawson, Claire A., et al.
Publicado: (2023)

Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report
por: Narang, Nikhil, et al.
Publicado: (2017)

Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction
por: Hage, Camilla, et al.
Publicado: (2020)

PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
por: Haraldsson, Inger, et al.
Publicado: (2019)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ospsgs3j6nn463kfav2r7vugo3